FDA Commissioner Dr. Robert Califf testified about the infant formula shortage today before a House subcommittee.
Califf was fiercely questioned by lawmakers on both sides of the aisle about the FDA's slow response to the crisis.
The FDA did not inspect a Sturgis, Michigan baby formula plant for months after the first reports of bacterial infections in infants were linked to the plant.
Califf acknowledged missteps by the FDA. And he said conditions at the Abbott plant were shocking, including standing water on floors and staff not following hygiene protocols. "This is so far removed from our previous experience with the company that I am very concerned," he said.
Califf says the FDA needs new funding for a supply chain tracking system for formula, to prevent future shortages.
The company Abbott, under FDA oversight, plans to reopen the Sturgis plant in early June.
An Abbott Nutrition Vice President also testified. He said he was “deeply, deeply sorry” about the shortages.
